Abstract
In the last 20 years, the advent of anti-tumor necrosis factor alpha (TNFα) biologics has revolutionized the treatment of patients with inflammatory bowel disease (IBD) but the cost of biologic therapy now constitutes a large proportion of all healthcare expenditures. Patent expiration has sparked the healthcare industry's interest in the production of biosimilar (BS) versions of first generation biologics (originators [ORGs]) for market sharing. Having no access to the production line of the ORG, the sponsor of a BS needs to develop his own manufacturing process to produce a highly similar version of the reference product. Similarity in structure, physicochemical properties, biologic activity, efficacy and safety must be demonstrated by a comprehensive comparability exercise that includes the most sensitive in vitro tests, models and clinical condition with pre-defined equivalence margins. Extrapolation of indications, inter-changeability and automatic substitution between BS and ORG depend on a legal framework that varies between different agencies. It is not, therefore, unexpected that marketing authorization by the European Medicines Agency and other regulatory agencies (but not Health Canada) of CT-P13 (Remsima™/Inflectra™) as infliximab (Remicade®) BSs for IBD by indication extrapolation has led to stormy discussions in the IBD community and beyond regarding the scientific adequacy of this decision. However, as we now have to live with BSs, we hope that the impeding automatic substitution in association with post-marketing pharmacovigilance, full traceability, registries and new studies will settle the controversy and will increase the confidence of physicians and patients. A universally adopted legal framework should be implemented because, as expected, the non-anti-TNFα BSs will be soon on the stage.
References
1.
Leader B, Baca QJ, Golan DE: Protein therapeutics: a summary and pharmacological classification. Nat Rev Drug Discov 2008;7:21-39.
2.
Tsiftsoglou AS, Ruiz S, Schneider CK: Development and regulation of biosimilars: current status and future challenges. BioDrugs 2013;27:203-211.
3.
Billiet T, Rutgeerts P, Ferrante M, Van Assche G, Vermeire S: Targeting TNF-α for the treatment of inflammatory bowel disease. Expert Opin Biol Ther 2014;14:75-101.
4.
Tsiftsoglou AS, Trouvin JH, Calvo G, Ruiz S: Demonstration of biosimilarity, extrapolation of indications and other challenges related to biosimilars in Europe. BioDrugs 2014;28:479-486.
5.
European Medicines Agency: Guideline on similar biological medicinal products. CHMP/437/04, London, 2005 (accessed October 30, 2005).
6.
European Medicines Agency: Guideline on similar biological medicinal products containing monoclonal antibodies - nonclinical and clinical issues. EMA/CHMP/BMWP/403543/2010, 2012 (accessed May 30, 2012).
7.
European Medicines Agency: Guideline on similar biological medicinal products. Draft, CHMP/437/04 Rev 1, 2013 (accessed April 26, 2013).
8.
Schneider CK, Borg JJ, Ehmann F, et al; Working Party on Similar Biological (Biosimilar) Medicinal Products (BMWP), Biologicals Working Party (BWP) of the Committee for Medicinal Products for Human Use (CHMP): In support of the European Union biosimilar framework. Nat Biotechnol 2012;30:745-748; author reply 478-479.
9.
Schneider CK, Vleminckx C, Gravanis I, Ehmann F, Trouvin JH, Weise M, Thirstrup S: Setting the stage for biosimilar monoclonal antibodies. Nat Biotechnol 2012;30:1179-1185.
10.
Health Products and Food Branch, Health Canada: Guidance for sponsors: information and submission requirements for subsequent entry biologics (SEBs). 2010. http://www.hc-sc.gc.ca/dhp-mps/alt_formats/pdf/brgtherap/applicdemande/guides/seb-pbu/seb-pbu-2010-eng.pdf (accessed February 4, 2014).
11.
US Food and Drug Administration: Guidance for industry: scientific considerations in demonstrating biosimilarity to a reference product (draft guidance). 2012. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf (accessed February 4, 2014).
12.
World Health Organization Expert Committee on Biological Standardization: Guidelines on evaluation of similar biotherapeutic products (SBP's). Geneva, World Health Organization, October 19-23, 2009. http://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf (accessed May 6, 2015).
13.
Remsima/European Public Assessment Report (EPAR). www.ema.europa.eu/docs/en_GB/document_library/EPAR_._Public_assessment_report/human/002576/WC50015486.pdf.
14.
Rinaudo-Gaujous M, Paul S, Tedesco ED, Genin C, Roblin X, Peyrin-Biroulet L: Review article: biosimilars are the next generation of drugs for liver and gastrointestinal diseases. Aliment Pharmacol Ther 2013;38:914-924.
15.
Gomollón F: Biosimilars in inflammatory bowel disease: ready for prime time? Curr Opin Gastroenterol 2015;31:290-295.
16.
Kim YS, Choi BW, Yang SW, et al: Biosimilars: challenges and path forward. Biotechnol Bioprocess Eng 2015;19:755-765.
17.
van der Valk ME, Mangen MJ, Leenders M, et al: Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study. Gut 2014;63:72-79.
18.
Jha A, Dunlop W, Upton A: Budget impact analysis of introducing biosimilar infliximab for the treatment of gastro intestinal disorders in five European countries. J Crohns Colitis 2015;9(suppl 1):S427.
19.
Ramanan S, Grampp G: Drift, evolution, and divergence in biologics and biosimilars manufacturing. BioDrugs 2014;28:363-372.
20.
Chirino AJ, Mire-Sluis A: Characterizing biological products and assessing comparability following manufacturing changes. Nat Biotechnol 2004;22:1383-1391.
21.
Berkowitz SA, Engen JR, Mazzeo JR, Jones GB: Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars. Nat Rev Drug Discov 2012;11:527-540.
22.
Szymczak MM, Friedman RL, Uppoor R, Yacobi A: Detection measurement, and control in pharma manufacturing. Pharm Technol 2011;35:70-76.
23.
US Food and Drug Administration: Guidance for industry: changes to an approved application for specified biotechnology and specified synthetic biological products. 1997. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm124805.pdf (accessed September 20, 2013).
24.
Lee JF, Litten JB, Grampp G: Comparability and biosimilarity considerations for the healthcare provider. Curr Med Res Opin 2012;28:1053-1058.
25.
Kresse GB: Biosimilars - science, status, and strategic perspective. Eur J Pharm Biopharm 2009;72:479-486.
26.
Feagan BG, Choquette D, Ghosh S, et al: The challenge of indication extrapolation for infliximab biosimilars. Biologicals 2014;42:177-183.
27.
Scientific considerations in demonstrating biosimilarity to a reference product. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf (accessed July 11, 2013).
28.
Strand V, Cronstein B: Biosimilars: how similar? Intern Med J 2014;44:218-223.
29.
European Medicines Agency: Annex to guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. Guidance on similar medicinal products containing recombinant granulocyte-colony stimulating factor (G-CSF). EMEA/CHMP/BMWP/31329/2005, London, 2006 (accessed February 22, 2006).
30.
Yoo DH, Hrycaj P, Miranda P, et al: A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis 2013;72:1613-1620.
31.
Park W, Hrycaj P, Jeka S, et al: A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis 2013;72:1605-1612.
32.
McClellan JE, Udata C, Yin D, et al: Comparative structural, functional, nonclinical, and phase 1 similarity assessments of PF-06438179, a potential biosimilar to infliximab, and marketed reference products. J Crohns Colitis 2015;9(suppl 1):S94.
33.
Danese S, Gomollón F: ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD). J Crohns Colitis 2013;7:586-589.
34.
Devlin SM, Bressler B, Bernstein CN, et al: Overview of subsequent entry biologics for the management of inflammatory bowel disease and Canadian Association of Gastroenterology position statement on subsequent entry biologics. Can J Gastroenterol 2013;27:567-571.
35.
Annese V, Vecchi M; Italian Group for the Study of IBD (IG-IBD): Use of biosimilars in inflammatory bowel disease: statements of the Italian group for inflammatory bowel disease. Dig Liver Dis 2014;46:963-968.
36.
Lee H: Is extrapolation of the safety and efficacy data in one indication to another appropriate for biosimilars? AAPS J 2014;16:22-26.
37.
Fiorino G, Danese S: The biosimilar road in inflammatory bowel disease: the right way? Best Pract Res Clin Gastroenterol 2014;28:465-471.
38.
Maini RN, Breedveld FC, Kalden JR, et al: Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-1563.
39.
Reinisch W, Smolen J: Biosimilar safety factors in clinical practice. Semin Arthritis Rheum 2015;44(6 suppl):S9-S15.
40.
Health Canada: Summary basis of decision e INFLECTRA. 2014. http://www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/drug-med/sbd_smd_2014_inflectra_159493-eng.php (accessed May 21, 2014).
41.
Ebbers HC: Biosimilars: in support of extrapolation of indications. J Crohns Colitis 2014;8:431-435.
42.
Kurki P, Bielsky MC; Working Party on Similar Biological (Biosimilar) Medicinal Products (BMWP) of Committee for Medicinal Products for Human Use (CHMP): ECCO position challenged by European drug regulators. J Crohns Colitis 2014;8:258.
43.
Takeuchi T, Yamanaka H, Tanaka Y, et al: Evaluation of the pharmacokinetic equivalence and 54-week efficacy and safety of CT-P13 and innovator infliximab in Japanese patients with rheumatoid arthritis. Mod Rheumatol 2015;25:817-824.
44.
Ben-Horin S, Yavzori M, Benhar I, et al: Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima. Gut 2015;pii:gutjnl-2015-309290.
45.
Farkas K, Rutka M, Bálint A, et al: Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn's disease and ulcerative colitis - experiences from a single center. Expert Opin Biol Ther 2015;15:1257-1262.
46.
Jung YS, Park DI, Kim YH, et al: Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: a retrospective multicenter study. J Gastroenterol Hepatol 2015, DOI: 10.1111/jgh.12997.
47.
Gecse K, Farkas K, Lovasz B, et al: Biosimilar infliximab in inflammatory bowel diseases: first interim results from a prospective nationwide observational cohort. J Crohns Colitis 2015;9(suppl 1):S331.
48.
Murphy C, Sugrue K, Mohamad G, McCarthy I, Buckley M: Biosimilars but not the same. J Crohns Colitis 2015;9(suppl 1):S331.
49.
Wieser C, Rosenkranz AR: Pure red cell aplasia after treatment of renal anaemia with epoetin theta. Clin Kidney J 2013;6:539-542.
50.
Directive 2010/84/EU of the European Parliament and of the Council of 15 December 2010 amending, as regards pharmacovigilance, directive 2001/83/EC on the Community code relating to medicinal products for human use. Off J Eur Union 2010;348:74-99.
51.
Danese S, Fiorino G, Michetti P: Viewpoint: knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn's and Colitis Organization. J Crohns Colitis 2014;8:1548-1550.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
